Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
1212/16 12/12/2016 idelalisib (Zydelig) Non submission

In combination with ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia:

  • who have received at least one prior therapy, or
  • first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
1039/15 11/05/2015 idelalisib (Zydelig) Full

Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
1026/15 09/03/2015 idelalisib (Zydelig) Full In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy, or as first line treatment in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

No medicines have been found.